Fujita M, Rudoltz M S, Canady D J, Patel P, Machtay M, Pittard M Q, Mohiuddin M, Regine W F
University of Kentucky, Department of Radiation Medicine, Lexington 40536-0084, USA.
Laryngoscope. 1998 Dec;108(12):1853-5. doi: 10.1097/00005537-199812000-00016.
OBJECTIVE/HYPOTHESIS: To evaluate incidence, site of occurrence and outcome of second malignant neoplasia (SMN) in patients with T1 glottic cancer treated with radiation.
Retrospective.
Between February 1964 and May 1993, 158 patients with T1 squamous carcinoma of the larynx were treated with definitive radiation. Incidence, site (aerodigestive tract or not) and outcome of SMN were analyzed. Median follow-up was 63 months (range, 12-245 mo).
Thirty-four patients developed SMN, for an overall incidence of 22%. Twenty-four (67%) SMNs occurred in an aero-upper-digestive-tract site compared with nine (25%) occurring in a non-aero-upper-digestive tract site. The incidence of SMN observed was higher than would be expected for the general population at risk. The observed-to-expected ratios (OER) for all SMN, aero-upper-digestive SMN and non-aero-upper-digestive SMNs were 1.73, 5.53, and 0.62, respectively. Overall 5- and 10-year survivals were 76% and 57%, respectively, for those who did not develop SMN, as compared with 68% and 26%, for those who developed SMN (P = .003). Overall, 13 patients (8.2%) have died from laryngeal cancer, while 23 (15%) died from SMN (P = .001).
This study confirms a higher incidence of SMN in T1 glottic cancer patients, compared with the general population. The majority of cases occur in aero-upper-digestive sites. These patients are more likely to die from their SMN than from glottic cancer. Patients with T1 squamous cell carcinoma of the glottic larynx represent a group of head and neck cancer patients who should be targeted in studies evaluating the potential benefits of chemoprevention, and aggressively counseled for social and/or behavioral modifications.
目的/假设:评估接受放射治疗的T1期声门癌患者发生第二原发性恶性肿瘤(SMN)的发生率、发生部位及转归。
回顾性研究。
1964年2月至1993年5月期间,158例T1期喉鳞状细胞癌患者接受了根治性放疗。分析SMN的发生率、发生部位(是否在气道消化道)及转归。中位随访时间为63个月(范围12 - 245个月)。
34例患者发生SMN,总发生率为22%。24例(67%)SMN发生在气道上消化道部位,9例(25%)发生在非气道上消化道部位。观察到的SMN发生率高于处于风险中的普通人群预期发生率。所有SMN、气道上消化道SMN和非气道上消化道SMN的观察与预期比值(OER)分别为1.73、5.53和0.62。未发生SMN的患者5年和10年总生存率分别为76%和57%,而发生SMN的患者分别为68%和26%(P = 0.003)。总体而言,13例(8.2%)患者死于喉癌,23例(15%)死于SMN(P = 0.001)。
本研究证实,与普通人群相比,T1期声门癌患者发生SMN的发生率更高。大多数病例发生在气道上消化道部位。这些患者死于SMN的可能性高于死于声门癌。声门T1期鳞状细胞癌患者是头颈癌患者群体中的一部分,在评估化学预防潜在益处的研究中应作为目标人群,并积极建议其进行社会和/或行为改变。